{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:32:50Z","timestamp":1792125170241,"version":"4.4.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Thus, recent guidelines do not recommend anymore allo-HSCT as consolidation in the first-line treatment of newly diagnosed MM, even in high-risk patients. In a relapsed\/refractory setting, allo-HSCT is not routinely recommended but should only be performed within clinical trials in young and high-risk patients. Nonetheless, allo-HSCT still represents a potential curative approach that has been used for decades in the treatment of MM and plasma cell neoplasms with favorable results and may still represent a treatment option for carefully selected patients. Despite that promising results were obtained with CAR T-cell therapies and bispecific antibodies in triple- and penta-exposed\/refractory MM, these patients will inevitably relapse. To date, less is known about outcomes of allo-HSCT in patients exposed to novel immunotherapeutic drugs. Therefore, allo-HSCT could represent a reasonable treatment choice for younger and high-risk patients who have relapsed after CAR T-cell therapies and bispecific antibodies as well as an alternative for patients not eligible to these treatments and in those countries where immunotherapies are not yet available. In the choice of conditioning, reduced intensity conditioning regimens are currently recommended for the lower toxicity and mortality. Moreover, the use of alternative donors, particularly haploidentical, has progressively increased in last years with results comparable to full matched donors. Finally, post-transplantation maintenance strategies are encouraged whenever feasible.<\/jats:p>","DOI":"10.3389\/fonc.2024.1402106","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:45:01Z","timestamp":1717479901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Allogeneic stem cell transplantation in multiple myeloma: is there still a place?"],"prefix":"10.3389","volume":"14","author":[{"given":"Carmine","family":"Liberatore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fioritoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Di Ianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19059","article-title":"Trends in hematopoietic stem cell transplantation for leukemia, lymphoma and multiple myeloma in the United","volume":"41","author":"Amadife","year":"2023","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"409.e1","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/bmt.2008.426","article-title":"CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT","volume":"43","author":"Kapp","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Pasquini","year":"2011","journal-title":"The Lancet Oncology."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kr\u00f6ger","year":"2009","journal-title":"Exp Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656635","article-title":"Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kro\u0308ger","year":"2004","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloma after allogeneic stem cell transplantation","volume":"24","author":"Gr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0887-4","article-title":"Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation","volume":"55","author":"Costa","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up","volume":"29","author":"Bj\u00f6rkstrand","year":"2011","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of post autologous hematopoietic cell transplantation strategies in the upfront treatment of multiple myeloma","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1154958","article-title":"Tandem autologous versus autologous\/allogeneic transplantation for multiple myeloma: propensity score analysis","volume":"57","author":"Kawamura","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.11.004","article-title":"Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model","volume":"10","author":"Ploemacher","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705605","article-title":"Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma","volume":"39","author":"Schmidt-Hieber","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16642","article-title":"Treosulfan conditioning for allogeneic transplantation in multiple myeloma \u2013 improved overall survival in first line haematopoietic stem cell transplantation \u2013 a large retrospective study by the Chronic Malignancies Working Party of the EBMT","volume":"189","author":"Gran","year":"2020","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143461","article-title":"Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12410","article-title":"Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients","volume":"162","author":"Caballero-Vel\u00e1zquez","year":"2013","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0670-6","article-title":"Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation","volume":"55","author":"Caballero-Vel\u00e1zquez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.026","article-title":"Phase II trial of allogeneic transplantation plus novel drugs in multiple myeloma: effect of intensifying reduced-intensity conditioning with bortezomib and adding maintenance treatment","volume":"28","author":"Reinoso-Segura","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01000-3","article-title":"90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma","volume":"56","author":"Tuazon","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.007","article-title":"Radioimmunotherapy in combination with reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with advanced multiple myeloma","volume":"26","author":"Fasslrinner","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","article-title":"Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial","volume":"26","author":"Giralt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282920","article-title":"Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study","volume":"109","author":"Kr\u00f6ger","year":"2024","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.37","article-title":"Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma","volume":"48","author":"Nishihori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: A systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99\u201303 trial) with tandem autologous stem cell transplantation (IFM99\u201304 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99\u201303 and IFM99\u201304 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kr\u00f6ger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.023","article-title":"Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma","volume":"29","author":"Afrough","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01007-w","article-title":"Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT","volume":"56","author":"Gagelmann","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-02278-5","volume-title":"The EBMT handbook","author":"Carreras","year":"2019"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the american society for blood and marrow transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.73","article-title":"Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: A study by the European group for blood and marrow transplantation","volume":"48","author":"Auner","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.012","article-title":"The role of allogeneic transplantation for multiple myeloma in the era of novel agents: A study from the Japanese society of myeloma","volume":"24","author":"Kawamura","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2020.08.003","article-title":"Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients \u2013 a single centre experience","volume":"193","author":"Jurgensen-Rauch","year":"2021","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2020.08.003","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group","volume":"65","author":"Go\u0142os","year":"2020","journal-title":"Adv Med Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.187","article-title":"Second transplants for multiple myeloma relapsing after a previous autotransplant\u2014reduced-intensity allogeneic vs autologous transplantation","volume":"49","author":"Freytes","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41408-023-00900-z","article-title":"Long-term outcomes of allogeneic stem cell transplant in multiple myeloma","volume":"13","author":"Schmidt","year":"2023","journal-title":"Blood Cancer J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.026","article-title":"Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability","volume":"18","author":"Patriarca","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.014","article-title":"Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation","volume":"24","author":"Patriarca","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01286-x","article-title":"Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party","volume":"56","author":"Hayden","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"Allogeneic stem cell transplantation in multiple myeloma: risk factors and outcomes in the era of new therapeutic options\u2014A single-center experience","volume":"15","author":"Strassl","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07984.x","article-title":"American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07984.x","article-title":"Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation: A prospective multicenter phase II study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"148","author":"Kr\u00f6ger","year":"2010","journal-title":"Br J Haematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165399","article-title":"Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the plasma cell disorders subcommittee of the european group for blood and marrow transplant chronic Malignancies working party","volume":"102","author":"Sobh","year":"2017","journal-title":"Haematologica"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.015","article-title":"Cord blood transplantation for multiple myeloma: A study from the multiple myeloma working group of the Japan society for hematopoietic cell transplantation","volume":"21","author":"Kawamura","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138917","article-title":"Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: A survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT","volume":"101","author":"Paviglianiti","year":"2016","journal-title":"Haematologica"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.018","article-title":"Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT\/CIBMTR report","volume":"25","author":"Sahebi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B67","doi-asserted-by":"crossref","first-page":"999.e1","DOI":"10.1016\/j.jtct.2021.09.008","article-title":"Post-transplantation cyclophosphamide for graft-versus- host disease prophylaxis in multiple myeloma patients who underwent allogeneic hematopoietic cell transplantation: first comparison by donor type. A study from the chronic Malignancies working party of the european society for blood and marrow transplantation","volume":"27","author":"Sahebi","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status","volume":"34","author":"Kr\u00f6ger","year":"2006","journal-title":"Exp Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01532-2","article-title":"Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous\/allogeneic transplant followed by bortezomib maintenance: a phase II study","volume":"57","author":"LeBlanc","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.007","article-title":"Bortezomib maintenance after allogeneic transplantation in newly diagnosed myeloma patients results in decreased incidence and severity of chronic GVHD","volume":"29","author":"Claveau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: results of the blood and marrow transplant clinical trials network 1302 trial","volume":"29","author":"Bashir","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.bbmt.2012.11.111","article-title":"Phase I\/II multicenter clinical trial of lenalidomide maintenance after allogeneic hematopoietic cell transplant (alloHCT) in patients with high risk (HR) multiple myeloma (MM)","volume":"19","author":"Becker","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kr\u00f6ger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023"},{"key":"B84","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches following BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1402106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:16:16Z","timestamp":1721384176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1402106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":87,"alternative-id":["10.3389\/fonc.2024.1402106"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1402106","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"article-number":"1402106"}}